Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles

BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the most common causes of end-stage renal failure, caused by mutations in PKD1 or PKD2 genes. Tolvaptan, the only drug approved for ADPKD treatment, results in serious side-effects, warranting the need for novel drugs. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Malas, Tareq B., Leonhard, Wouter N., Bange, Hester, Granchi, Zoraide, Hettne, Kristina M., Van Westen, Gerard J.P., Price, Leo S., 't Hoen, Peter A.C., Peters, Dorien J.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000333/
https://www.ncbi.nlm.nih.gov/pubmed/31879244
http://dx.doi.org/10.1016/j.ebiom.2019.11.046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000333/
https://www.ncbi.nlm.nih.gov/pubmed/31879244
http://dx.doi.org/10.1016/j.ebiom.2019.11.046

Ejemplares similares